
-
Replimune Group Inc NASDAQ:REPL Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune's Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.
Location: 500 Unicorn Park Dr, Massachusetts, 01801-3377, United States | Website: www.replimune.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
616.2M
Cash
536.5M
Avg Qtr Burn
-46.17M
Short % of Float
15.99%
Insider Ownership
4.18%
Institutional Own.
-
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date | |
---|---|---|---|
RP2 in comb w/ atezolizumab and bevacizumab Details Cancer, Hepatocellular carcinoma | No event data in pipeline | | |
RP1 +Opdivo (nivolumab) Details Cancer, Melanoma | PDUFA Approval decision | ||
RP2 + Opdivo Details Cancer, Uveal melanoma | Phase 2/3 Data readout | ||
RP1 + Opdivo Details Cancer, Non-melanoma skin cancer | Phase 2 Update | ||
RP1 + Libtayo (cemiplimab) Details Cutaneous squamous cell carcinoma, Cancer | Phase 2 Update | ||
RP1 Details Cancer, Cutaneous squamous cell carcinoma, Kidney transplantation, Liver transplant, Skin cancer | Phase 1/2 Data readout | ||
RP2 +/- Opdivo Details Solid tumor/s, Cancer, Breast cancer, Head and neck cancer, Lung cancer, Hepatocellular carcinoma | Phase 1 Update | ||
RP3 in comb w/std. of care Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued | ||
(RP3 & RP2) in comb w/atezolizumab and bevacizumab Details Cancer, Colorectal cancer , Hepatocellular carcinoma | Failed Discontinued | ||
RP3 +/- Opdivo Details Solid tumor/s, Cancer, Lung cancer, Breast cancer, Head and neck cancer | Failed Discontinued |